CRL News Alert Charles River Laboratories Intl (CRL) 63.59 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Charles River Laboratories Intl (CRL) 63.59 $CRL

Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:50PM CST
Pharmacy benefit manager Express Scripts (ESRX) announced an update to its National Preferred Formulary, which will now include AbbVie's (ABBV) recently approved new medication for hepatitis C, Viekira Pak.
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), CRL: 63.59 (+0.33)

Healthways-TAL to Improve Well-Being Solutions in Australia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:25PM CST
Healthways Inc. (HWAY) recently entered into a partnership with Australia's specialty life insurer TAL to jointly provide improvement solutions for the latter's members.
EVHC: 35.59 (+0.23), HWAY: 19.88 (+0.13), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72)

ICON (ICLR) Now a Strong Buy: Should It Be in Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:00PM CST
ICON has been witnessing rising earnings estimates on the back of a new FDA project and an increased guidance for fiscal 2014.
EVHC: 35.59 (+0.23), HQY: 25.59 (+0.24), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72)

Cancer Genetics (CGIX) Looks Good: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:25AM CST
Cancer Genetics (CGIX) was a big mover last session, with shares rising just over 8% on the day.
Q: 59.48 (+0.01), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72), CGIX: 7.12 (+0.06)

BioTelemetry (BEAT) Catches Eye: Stock Jumps 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:30AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
EVHC: 35.59 (+0.23), BEAT: 10.15 (+0.09), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72)

Charles River Laboratories Earnings In Retrospect: Down 1.1% in the Last 19 Days (CRL)
Comtex SmarTrend(R) - Mon Nov 17, 10:43AM CST
When Charles River Laboratories (NYSE:CRL) reported earnings 19 days ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.80 on sales of $326.8 million. The company actually reported EPS of $0.86 on sales of $327.6 million, beating EPS estimates by $0.06 and beating revenue estimates by $0.8 million. Shares of Charles River Laboratories have slipped from $64.47 to $63.76, representing a loss of 1.1%, since the company reported earnings 19 days ago.
CRL: 63.59 (+0.33)

Intrexon (XON) Looks Good: Stock Moves 11% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:46AM CST
Intrexon (XON) was a big mover last session, with shares rising almost 11% on the day.
BEAT: 10.15 (+0.09), XON: 26.19 (+0.67), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72)

Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 56.48 (+0.57), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72), CVD: 103.73 (+0.02)

Strength Seen in Covance (CVD): Stock Surges 25.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:25AM CST
Covance (CVD) was a big mover last session, with shares surging nearly 26% on the day.
BEAT: 10.15 (+0.09), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72), CVD: 103.73 (+0.02)

Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 11.25 (+0.11), TTWO: 28.60 (+0.18), BIIB: 340.89 (+5.13), GILD: 91.29 (+1.84), CRL: 63.59 (+0.33), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Cramer's Mad Money - Charles River Labs Battles Ebola (10/30/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Oct 31, 4:46AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday October 30. CEO Interview: James Foster, Charles River Labs (NYSE: CRL ) Cramer spoke with James Foster, CEO of Charles River Labs ( CRL ). The company...
FLEX: 11.25 (+0.11), MMM: 166.96 (+0.09), BIIB: 340.89 (+5.13), CLR: 38.78 (-1.48), HON: 101.96 (-0.02), FB: 80.77 (+0.16), DIS: 94.42 (-0.27), BMY: 59.15 (-0.01), CELG: 109.60 (+3.48), SBUX: 81.27 (-0.16), WWAV: 35.98 (+0.72), HAIN: 117.25 (+0.23), UA: 67.97 (+0.18), TTWO: 28.60 (+0.18), RDS.B: 71.06 (+0.08), RDS.A: 68.42 (-0.31), TJX: 67.87 (-0.25), GILD: 91.29 (+1.84), CMG: 672.79 (+3.58), COST: 143.65 (-0.50), BP: 38.95 (-0.17), ARCP: 8.33 (unch), CRL: 63.59 (+0.33), AAPL: 112.01 (-0.53), REGN: 400.12 (+6.07), WEN: 8.99 (+0.14)

Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 166.96 (+0.09), BIIB: 340.89 (+5.13), HON: 101.96 (-0.02), FB: 80.77 (+0.16), BMY: 59.15 (-0.01), MGM: 20.77 (-0.17), ATK: 113.52 (+0.59), YRCW: 23.52 (-0.15), UPS: 112.41 (-0.04), SLB: 87.06 (-0.26), CELG: 109.60 (+3.48), WPRT: 3.74 (+0.15), SBUX: 81.27 (-0.16), TTWO: 28.60 (+0.18), DO: 38.66 (-0.62), ETP: 63.95 (+0.35), GILD: 91.29 (+1.84), ARR: 3.69 (-0.01), CMG: 672.79 (+3.58), MPEL: 24.81 (+0.20), WNC: 12.24 (+0.07), CRL: 63.59 (+0.33), AAPL: 112.01 (-0.53), REGN: 400.12 (+6.07)

Charles River Laboratories International's (CRL) CEO James Foster on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 1:50PM CDT

CRL: 63.59 (+0.33)

Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 210.12 (+0.95), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), CRL: 63.59 (+0.33)

Charles River Laboratories raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 9:53AM CDT

CRL: 63.59 (+0.33)

Charles River Laboratories International In (CRL) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Thu Oct 30, 9:04AM CDT
Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
CRL: 63.59 (+0.33)

Charles River beats Street 3Q forecasts
Automated Insights - Wed Oct 29, 5:45PM CDT
WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $32 million.
CRL: 63.59 (+0.33)

Ampersand Exits ChanTest Investment
PR Newswire - Wed Oct 29, 3:56PM CDT
Ampersand Capital Partners is pleased to announce the successful sale of Cleveland, Ohio based ChanTest, a leading provider of specialized laboratory testing services for drug development. ChanTest has been acquired by Charles River Laboratories International, Inc. in an all-cash transaction.
CRL: 63.59 (+0.33)

Charles River Laboratories beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:30PM CDT

CRL: 63.59 (+0.33)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 10

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Antonio Filosa Takes the Helm as CEO of Stellantis N.V.

Updated Category News Views 335

Antonio Filosa Appointed as Stellantis N.V. Chief Executive Officer Stellantis N.V., a prominent player in the global automotive arena, has officially announced the appointment of Antonio Filosa as its new Chief Executive Officer. Filosa, who has amassed over 25 years of experience within the automotive sector, currently holds the position of Chief Operating Officer for...

Continue Reading
Understanding the Edwards Lifesciences Legal Landscape

Updated Category News Views 278

Understanding Recent Legal Issues for Investors In the world of investment, understanding legal implications can often feel overwhelming, especially when a company faces a class action lawsuit. Edwards Lifesciences Corporation, a name recognized for its innovative heart valve technologies, currently finds itself embroiled in legal battles that could shape its future and...

Continue Reading
Arrive Home and FormFree Join Forces to Enhance Homeownership Access

Updated Category News Views 155

Arrive Home Partners with FormFree for Innovative Solutions The innovative collaboration between Arrive Home and FormFree aims to transform the landscape of homeownership for many borrowers facing challenges due to limited credit histories. This partnership is particularly significant as it opens doors for those who have previously been overlooked by traditional credit...

Continue Reading
Verizon's $20 Billion Acquisition: A Strategic Expansion Ahead

Updated Category News Views 76

Verizon Announces Major Acquisition of Frontier Communications Verizon has recently made headlines by announcing a significant acquisition deal with Frontier Communications. This all-cash transaction, valued at $20 billion, underscores Verizon's dedication to substantially expanding its fiber network. Details of the Acquisition According to the proposed terms, Verizon...

Continue Reading
MoxiWorks Enhances Innovation Timeline with New Leadership and Funding

Updated Category News Views 174

MoxiWorks Enhances Innovation Timeline with New Leadership and Funding Funding from private equity and brokerage partners, along with new leadership, is set to transform MoxiWorks, a leading provider of sales and marketing software in the real estate sector. With substantial capital secured from its ownership group, which includes Vector Capital, Howard Hanna Real Estate...

Continue Reading